Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 15;8(1):281-285.
doi: 10.31662/jmaj.2024-0242. Epub 2024 Nov 11.

Temporal Changes in HbA1c Levels after Sacubitril/Valsartan Initiation in a Real-world Japanese Cohort: REVIEW-HF Registry

Yukihiro Watanabe  1 , Yoshiaki Kubota  1 , Takuya Nishino  2 , Takahito Nasu  3 , Shunsuke Ishii  4 , Nobuyuki Kagiyama  5   6 , Keisuke Kida  7 , Wataru Fujimoto  8 , Koshiro Kanaoka  9   10 , Shingo Matsumoto  11   12
Affiliations

Temporal Changes in HbA1c Levels after Sacubitril/Valsartan Initiation in a Real-world Japanese Cohort: REVIEW-HF Registry

Yukihiro Watanabe et al. JMA J. .
No abstract available

Keywords: Asia; Diabetes; Glycemic control; Heart failure; Sacubitril/valsartan.

PubMed Disclaimer

Conflict of interest statement

N.K. has received honoraria from Novartis Pharma, Boehringer Ingelheim Japan, Eli Lilly Japan K.K., and Otsuka Pharma and is affiliated with a department endowed by AMI Inc., Fukuda Denshi, KYOCERA, InterReha, and Philips Japan. K.K. has received honoraria from Otsuka Pharmaceutical Co., Ltd.; Novartis Pharmaceuticals Co., Ltd.; AstraZeneca K.K.; Ono Pharmaceutical Co., Ltd.; and Nippon Boehringer Ingelheim Co., Ltd. S.M. has received research grants and personal fees from Abott, Bayer Pharma, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Novartis, Ono Pharma, Orbus Neich, Otsuka Pharma, and the Uehara Memorial Foundation. The remaining authors declare that there are no conflicts of interest.

Figures

Figure 1.
Figure 1.
Temporal changes in HbA1c levels after sacubitril/valsartan initiation. HbA1c levels significantly decreased at 3, 6, and 12 months compared with baseline levels (P values for pairwise comparisons of estimated marginal means with Bonferroni adjustment). Error bars represent 95% confidence intervals.
Figure 2.
Figure 2.
Subgroup analyses. Patients with diabetes showed a significantly greater decrease in HbA1c levels than those without diabetes. BMI, body mass index; LVEF, left ventricular ejection fraction; SGLT2, sodium-glucose cotransporter-2.
See this image and copyright information in PMC

References

    1. Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333-40. - PMC - PubMed
    1. Wijkman MO, Claggett B, Vaduganathan M, et al. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022;21(1):110. - PMC - PubMed
    1. Ryu R, Tran H, Bahjri K. Association of Sacubitril/Valsartan with metabolic parameters in patients with reduced ejection fraction heart failure at a multidisciplinary clinic. Metab Syndr Relat Disord. 2021;19(2):115-8. - PubMed
    1. Armentaro G, D'Arrigo G, Miceli S, et al. Long term metabolic effects of Sacubitril/Valsartan in non-diabetic and diabetic patients with heart failure reduced ejection fraction: a real life study. Front Physiol. 2022;13:897109. - PMC - PubMed
    1. Cloro C, Zaffina I, Sacchetta L, et al. Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction. Front Endocrinol. 2022;13:940654. - PMC - PubMed

LinkOut - more resources